Hepatic Porphyria
📧 Sign up to get email alerts when something new happens for Hepatic Porphyria.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS approval · 2024-05-20Clinical Trial Update: Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
The document indicates that the expanded access protocol for givosiran in acute hepatic porphyria has been approved for marketing.
-
FDA approval · 2024-04-29FDA Approved: GIVLAARI — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GIVLAARI (givosiran) filed by Alnylam Pharmaceuticals, updating the drug's labeling/indicati…
-
FDA approval · 2023-02-10FDA Approved: GIVLAARI — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GIVLAARI (givosiran) from Alnylam Pharmaceuticals.
-
FDA approval · 2021-10-28FDA Approved: GIVLAARI — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
The FDA has approved a supplemental application for GIVLAARI (givosiran) by Alnylam Pharmaceuticals.
-
EMA approval · 2020-01-31First treatment for acute hepatic porphyria
The EMA announces the first treatment for acute hepatic porphyria, signaling a new approved therapy for this condition.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-11-20FDA Approved: GIVLAARI — Original Application (Alnylam Pharmaceuticals, Inc.)
The FDA approved GIVLAARI (givosiran) in an Original Application for the treatment of acute hepatic porphyria, marking the drug's initial ap…